Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials
Pooling randomized trials of patients with reduced kidney function (eGFR below 60), GLP-1 receptor agonists lowered the risk of kidney disease progression, cardiovascular events, and death.
Background
GLP-1 receptor agonists improve cardiac and kidney outcomes in diabetes, but their efficacy specifically in patients with reduced eGFR (established CKD) was uncertain.
Study design
This systematic review and meta-analysis pooled randomized controlled trials reported through May 2024 that enrolled adults with baseline eGFR below 60 mL/min/1.73 m2 comparing GLP-1 receptor agonists with control, using random-effects models and GRADE certainty assessment.
Key findings
Among 17,996 participants with eGFR below 60, GLP-1 receptor agonists reduced the composite kidney outcome (OR 0.85; 95% CI 0.77-0.94), greater than 50% eGFR decline (OR 0.72), all-cause mortality (OR 0.77; 95% CI 0.60-0.98), and composite cardiovascular outcomes (OR 0.86; 95% CI 0.74-0.99).
Clinical implications
GLP-1 receptor agonists improved kidney and cardiovascular outcomes and survival in patients with established CKD, supporting their broader use in diabetic CKD, though most included populations had diabetes and kidney outcome definitions varied.
Category
Research
Source
American Journal of Kidney Diseases
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.